BioAlliance Pharma Out-licenses Loramyc in China to NovaMed Pharma

June 24, 2008 -- BioAlliance Pharma SA (Euronext Paris: BIO) has licensed the China commercialization rights for Loramyc™ to NovaMed Pharmaceuticals. The deal could be worth up to $4.5 million to NovaMed in upfront and milestone payments. NovaMed will seek to win SFDA approval for the product and then market it in China. Loramyc (miconazole Lauriad®) is a muco-adhesive antifungal therapy that is already approved in some European countries for cancer patients with opportunistic infections. More details...